Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16.02

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $16.02 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Pharmacyclics LLC, An AbbVie Company $16.02 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $16.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $16.0208/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998286895 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

294 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2025 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab No dispute reported 06/30/2026 1202533087
Principal investigator 1 Merck Sharp & Dohme LLC $4,131.05 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01 No dispute reported 06/30/2026 1232921936
Principal investigator 1 Merck Sharp & Dohme LLC $5,746.60 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC IDeate-Prostate01 No dispute reported 06/30/2026 1232923174
Principal investigator 1 Merck Sharp & Dohme LLC $4,686.01 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232925913
Principal investigator 1 Merck Sharp & Dohme LLC $8,061.04 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 1232926503
Principal investigator 1 Merck Sharp & Dohme LLC $17,898.42 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor No dispute reported 06/30/2026 1232930381
Principal investigator 1 Merck Sharp & Dohme LLC $11,014.20 12/31/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934908
Principal investigator 1 Merck Sharp & Dohme LLC $911.24 12/31/2025 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232935613
Principal investigator 1 Merck Sharp & Dohme LLC $346.09 12/31/2025 Non-covered Recipient Entity
Nebraska Cancer Specialists
An Open Label, First in Human FIH, Phase 1 Trial of LVGN6051 as Single Agent and in Combination with Keytruda pembrolizumab in Advanced or Metastatic Malignancy No dispute reported 06/30/2026 1232936228
Principal investigator 1 ABBVIE INC. $337.50 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202530406
Principal investigator 1 ABBVIE INC. $2,295.00 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202530408
Principal investigator 1 ABBVIE INC. $2,295.00 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202530420
Principal investigator 1 ABBVIE INC. $337.50 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202530422
Principal investigator 1 ABBVIE INC. $348.30 12/15/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202530424
Principal investigator 1 Merck Sharp & Dohme LLC $12,476.00 12/15/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934906
Principal investigator 1 BioNTech SE $201.50 12/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020215
Principal investigator 1 BioNTech SE $582.40 12/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020217
Principal investigator 1 BioNTech SE $8,359.00 12/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020235
Principal investigator 1 BioNTech SE $500.00 12/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020237
Principal investigator 1 BioNTech SE $276.00 12/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020239
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 12/09/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211635132
Principal investigator 1 ABBVIE INC. $750.00 12/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202526132
Principal investigator 1 ABBVIE INC. $4,000.00 12/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202526134
Principal investigator 1 ABBVIE INC. $476.55 11/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202525836
Principal investigator 1 BioNTech SE $11,758.50 11/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111 No dispute reported 06/30/2026 1249020213
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 11/18/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1211635121
Principal investigator 1 Hoffmann-La Roche Limited $2,500.00 11/18/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1211635127
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910683
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910685
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910687
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910689
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910691
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910693
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910695
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910697
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910699
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910701
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910715
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910717
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910719
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910721
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910723
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,000.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910725
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910727
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910729
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910731
Principal investigator 1 Aveo Pharmaceuticals, Inc. $900.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910733
Principal investigator 1 Aveo Pharmaceuticals, Inc. $150.00 11/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910735
Principal investigator 1 ABBVIE INC. $187.00 11/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519979
Principal investigator 1 ABBVIE INC. $187.00 11/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519981
Principal investigator 1 ABBVIE INC. $374.00 11/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519983
Principal investigator 1 ABBVIE INC. $2,114.10 10/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518507
Recipient Novartis Pharma AG $431.05 10/19/2025 Covered Recipient Physician CAAA617C12301 No dispute reported 06/30/2026 1248109525
Principal investigator 1 ABBVIE INC. $337.50 10/16/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517089
Principal investigator 1 ABBVIE INC. $2,295.00 10/16/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517091
Principal investigator 1 ABBVIE INC. $337.50 10/16/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517093
Principal investigator 1 ABBVIE INC. $2,295.00 10/16/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517095
Principal investigator 1 ABBVIE INC. $187.00 10/09/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513647
Principal investigator 1 Amgen Inc. $596.00 10/08/2025 Non-covered Recipient Entity
WESTERN INSTITUTIONAL REVIEW
A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Xaluritamig in Combination with Androgen Receptor Pathway Inhibitor in Participants with Metastatic Hormone-Sensitive Prostate Cancer No dispute reported 06/30/2026 1246652208
Principal investigator 1 ABBVIE INC. $6,750.00 10/06/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513247
Principal investigator 1 ABBVIE INC. $337.50 10/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513177
Principal investigator 1 ABBVIE INC. $348.30 10/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513179
Principal investigator 1 ABBVIE INC. $2,295.00 10/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513185
Principal investigator 1 ABBVIE INC. $2,295.00 10/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513187
Principal investigator 1 ABBVIE INC. $337.50 10/03/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202513223
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,450.00 09/24/2025 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer No dispute reported 06/30/2026 1190304765
Principal investigator 1 BioNTech SE $416.50 09/23/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020095
Recipient Novartis Pharma AG $178.25 09/09/2025 Covered Recipient Physician CAAA617C12301 No dispute reported 06/30/2026 1248109527
Principal investigator 1 Astellas Pharma Global Development $500.00 09/04/2025 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180180
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,916.92 09/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C DBA NEBRASKA CANCER SPECIALIST
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305847
Principal investigator 1 ABBVIE INC. $2,390.85 08/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202506557
Principal investigator 1 ABBVIE INC. $3,653.10 08/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202506559
Principal investigator 1 ABBVIE INC. $1,031.40 08/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202506567
Principal investigator 1 Astellas Pharma Global Development $399.44 08/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184521
Principal investigator 1 Astellas Pharma Global Development $399.44 08/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184523
Principal investigator 1 Astellas Pharma Global Development $399.44 08/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184525
Principal investigator 1 Astellas Pharma Global Development $399.44 08/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184527
Principal investigator 1 Astellas Pharma Global Development $399.44 08/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184529
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910553
Principal investigator 1 Aveo Pharmaceuticals, Inc. $350.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910555
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,525.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910557
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910559
Principal investigator 1 Aveo Pharmaceuticals, Inc. $350.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910561
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,525.00 08/14/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910563
Principal investigator 1 Exelixis Inc. $3,600.00 08/08/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222383008
Principal investigator 1 ABBVIE INC. $337.50 08/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202500994
Principal investigator 1 ABBVIE INC. $2,295.00 08/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202500996
Principal investigator 1 ABBVIE INC. $337.50 08/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202500998
Principal investigator 1 ABBVIE INC. $348.30 08/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202501000
Principal investigator 1 ABBVIE INC. $2,295.00 08/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202501002
Principal investigator 1 Astellas Pharma Global Development $464.00 07/31/2025 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180178
Principal investigator 1 BioNTech SE $416.50 07/31/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020097
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,500.00 07/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199909523
Principal investigator 1 Aveo Pharmaceuticals, Inc. $17,280.00 07/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199909525
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,200.00 07/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199909527
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,400.00 07/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels No dispute reported 06/30/2026 1199909529
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 07/28/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910565
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 07/28/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910567
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910569
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910571
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910573
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910601
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910607
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910609
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910611
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910613
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910615
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910617
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910621
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910623
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910627
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910629
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910631
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910639
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910641
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910645
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910647
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,349.00 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910655
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910657
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910665
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910679
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 06/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910681
Principal investigator 1 ABBVIE INC. $4,230.90 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493393
Principal investigator 1 ABBVIE INC. $2,659.50 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493401
Principal investigator 1 ABBVIE INC. $1,031.40 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493405
Principal investigator 1 ABBVIE INC. $2,899.80 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493415
Principal investigator 1 ABBVIE INC. $4,603.50 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493417
Principal investigator 1 ABBVIE INC. $3,339.90 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493419
Principal investigator 1 ABBVIE INC. $1,422.90 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493421
Principal investigator 1 ABBVIE INC. $1,031.40 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493427
Principal investigator 1 ABBVIE INC. $1,776.60 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493429
Principal investigator 1 ABBVIE INC. $476.55 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493431
Principal investigator 1 ABBVIE INC. $2,390.85 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493433
Principal investigator 1 ABBVIE INC. $1,422.90 06/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493445
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910603
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910605
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910619
Principal investigator 1 Aveo Pharmaceuticals, Inc. $283.00 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910625
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910635
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910637
Principal investigator 1 Aveo Pharmaceuticals, Inc. $3,525.00 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910643
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910649
Principal investigator 1 Aveo Pharmaceuticals, Inc. $262.00 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910651
Principal investigator 1 Aveo Pharmaceuticals, Inc. $350.00 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910653
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910659
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,617.00 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910661
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910663
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 06/20/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910677
Principal investigator 1 BioNTech SE $250.00 06/19/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020077
Principal investigator 1 BioNTech SE $1,500.00 06/19/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020079
Principal investigator 1 BioNTech SE $900.00 06/19/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020081
Principal investigator 1 ABBVIE INC. $3,037.50 06/13/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202491405
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,000.00 06/12/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C DBA NEBRASKA CANCER SPECIALIST
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190305845
Principal investigator 1 Astellas Pharma Global Development $565.00 06/05/2025 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180176
Principal investigator 1 ABBVIE INC. $6,750.00 06/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202487201
Principal investigator 1 ABBVIE INC. $2,295.00 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486589
Principal investigator 1 ABBVIE INC. $1,066.50 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486591
Principal investigator 1 ABBVIE INC. $6,750.00 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486593
Principal investigator 1 ABBVIE INC. $2,295.00 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486595
Principal investigator 1 ABBVIE INC. $675.00 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486597
Principal investigator 1 ABBVIE INC. $1,205.55 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486599
Principal investigator 1 ABBVIE INC. $3,750.30 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486601
Principal investigator 1 ABBVIE INC. $348.30 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486603
Principal investigator 1 ABBVIE INC. $1,188.00 05/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202486605
Principal investigator 1 Merck Sharp & Dohme LLC $2,899.00 05/14/2025 Non-covered Recipient Entity
Oncology Hematology West, PC dba Nebraska Cancer Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232925911
Principal investigator 1 Astellas Pharma Global Development $2,191.53 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184481
Principal investigator 1 Astellas Pharma Global Development $3,158.49 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184483
Principal investigator 1 Astellas Pharma Global Development $999.87 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184485
Principal investigator 1 Astellas Pharma Global Development $2,160.89 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184487
Principal investigator 1 Astellas Pharma Global Development $2,160.89 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184489
Principal investigator 1 Astellas Pharma Global Development $2,191.53 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184491
Principal investigator 1 Astellas Pharma Global Development $1,500.00 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184493
Principal investigator 1 Astellas Pharma Global Development $1,358.50 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184495
Principal investigator 1 Astellas Pharma Global Development $2,179.05 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184497
Principal investigator 1 Astellas Pharma Global Development $2,210.83 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184499
Principal investigator 1 Astellas Pharma Global Development $2,191.53 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184501
Principal investigator 1 Astellas Pharma Global Development $2,179.05 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184503
Principal investigator 1 Astellas Pharma Global Development $750.00 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184505
Principal investigator 1 Astellas Pharma Global Development $2,210.83 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184507
Principal investigator 1 Astellas Pharma Global Development $2,799.37 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184509
Principal investigator 1 Astellas Pharma Global Development $1,358.50 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184511
Principal investigator 1 Astellas Pharma Global Development $3,158.49 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184513
Principal investigator 1 Astellas Pharma Global Development $1,358.50 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184515
Principal investigator 1 Astellas Pharma Global Development $2,160.89 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184517
Principal investigator 1 Astellas Pharma Global Development $2,210.83 05/01/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1234184519
Principal investigator 1 ABBVIE INC. $2,632.50 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479933
Principal investigator 1 ABBVIE INC. $1,031.40 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479935
Principal investigator 1 ABBVIE INC. $3,404.70 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479941
Principal investigator 1 ABBVIE INC. $1,474.20 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479943
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479945
Principal investigator 1 ABBVIE INC. $1,864.35 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480081
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480189
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480191
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480193
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480195
Principal investigator 1 ABBVIE INC. $21.44 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480219
Principal investigator 1 ABBVIE INC. $1,339.20 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480221
Principal investigator 1 ABBVIE INC. $1,831.95 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480223
Principal investigator 1 ABBVIE INC. $2,185.65 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480237
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480257
Principal investigator 1 ABBVIE INC. $1,140.75 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480259
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480269
Principal investigator 1 ABBVIE INC. $3,609.90 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480271
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480273
Principal investigator 1 ABBVIE INC. $1,339.20 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480275
Principal investigator 1 ABBVIE INC. $2,114.10 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480277
Principal investigator 1 ABBVIE INC. $3,339.90 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480279
Principal investigator 1 ABBVIE INC. $51.00 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480291
Principal investigator 1 ABBVIE INC. $1,031.40 04/30/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480293
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 04/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910669
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 04/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910671
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 04/30/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910675
Principal investigator 1 ABBVIE INC. $675.00 04/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479674
Principal investigator 1 ABBVIE INC. $2,295.00 04/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479690
Principal investigator 1 ABBVIE INC. $2,295.00 04/28/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202479721
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,505.60 04/28/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910667
Principal investigator 1 ABBVIE INC. $2,295.00 04/23/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202478457
Principal investigator 1 ABBVIE INC. $1,012.50 04/23/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202478479
Principal investigator 1 ABBVIE INC. $2,295.00 04/23/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202478491
Principal investigator 1 ABBVIE INC. $2,295.00 04/23/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202478495
Principal investigator 1 Merck Sharp & Dohme LLC $120,200.00 04/22/2025 Non-covered Recipient Entity
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932713
Principal investigator 1 Merck Sharp & Dohme LLC $242,400.00 04/17/2025 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232935615
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 04/09/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910673
Principal investigator 1 ABBVIE INC. $337.50 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468154
Principal investigator 1 ABBVIE INC. $1,236.60 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468159
Principal investigator 1 ABBVIE INC. $337.50 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468244
Principal investigator 1 ABBVIE INC. $675.00 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468267
Principal investigator 1 ABBVIE INC. $3,069.90 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468271
Principal investigator 1 ABBVIE INC. $2,295.00 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468274
Principal investigator 1 ABBVIE INC. $4,590.00 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468278
Principal investigator 1 ABBVIE INC. $303.75 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468283
Principal investigator 1 ABBVIE INC. $6,750.00 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468286
Principal investigator 1 ABBVIE INC. $3,404.70 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468289
Principal investigator 1 ABBVIE INC. $2,295.00 04/02/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202468307
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467032
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467037
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467042
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467046
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467050
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467055
Principal investigator 1 ABBVIE INC. $51.00 03/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202467057
Principal investigator 1 ABBVIE INC. $1,020.60 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465937
Principal investigator 1 ABBVIE INC. $1,339.20 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465942
Principal investigator 1 ABBVIE INC. $2,114.10 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465978
Principal investigator 1 ABBVIE INC. $1,831.95 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465982
Principal investigator 1 ABBVIE INC. $1,948.05 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465986
Principal investigator 1 ABBVIE INC. $3,609.90 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465989
Principal investigator 1 ABBVIE INC. $1,339.20 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465993
Principal investigator 1 ABBVIE INC. $3,339.90 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202465997
Principal investigator 1 ABBVIE INC. $2,632.50 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466001
Principal investigator 1 ABBVIE INC. $3,172.50 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466005
Principal investigator 1 ABBVIE INC. $1,339.20 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466009
Principal investigator 1 ABBVIE INC. $3,404.70 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466012
Principal investigator 1 ABBVIE INC. $3,609.90 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466016
Principal investigator 1 ABBVIE INC. $1,031.40 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466021
Principal investigator 1 ABBVIE INC. $2,218.05 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466024
Principal investigator 1 ABBVIE INC. $1,339.20 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466028
Principal investigator 1 ABBVIE INC. $2,185.65 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466036
Principal investigator 1 ABBVIE INC. $1,031.40 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466039
Principal investigator 1 ABBVIE INC. $1,831.95 03/25/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202466044
Principal investigator 1 Exelixis Inc. $1,000.00 03/24/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222383018
Principal investigator 1 Exelixis Inc. $1,500.00 03/24/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma No dispute reported 06/30/2026 1222383020
Principal investigator 1 Astellas Pharma Global Development $1,029.00 03/20/2025 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1234180174
Principal investigator 1 ABBVIE INC. $235.84 03/19/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202464421
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,700.00 03/13/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910517
Principal investigator 1 BioNTech SE $416.50 03/11/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1249020055
Principal investigator 1 ABBVIE INC. $6,750.00 03/05/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202456112
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 02/27/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910511
Principal investigator 1 Aveo Pharmaceuticals, Inc. $175.00 02/24/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910507
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.00 02/17/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910509
Principal investigator 1 Novartis Pharmaceuticals Corporation $53,856.44 02/04/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C DBA NEBRASKA CANCER SPECIALIST
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305849
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 02/03/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910505
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 02/03/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910513
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 02/03/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910515
Principal investigator 1 ABBVIE INC. $2,295.00 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441957
Principal investigator 1 ABBVIE INC. $1,911.60 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441962
Principal investigator 1 ABBVIE INC. $337.50 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441967
Principal investigator 1 ABBVIE INC. $1,020.60 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441978
Principal investigator 1 ABBVIE INC. $757.35 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442269
Principal investigator 1 ABBVIE INC. $2,301.75 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442322
Principal investigator 1 ABBVIE INC. $757.35 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442325
Principal investigator 1 ABBVIE INC. $2,295.00 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442402
Principal investigator 1 ABBVIE INC. $337.50 01/29/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442437
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 01/29/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910521
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 01/29/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910523
Principal investigator 1 ABBVIE INC. $187.00 01/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441298
Principal investigator 1 ABBVIE INC. $187.00 01/27/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202441377
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $28,334.30 01/23/2025 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1235994878
Principal investigator 1 AstraZeneca Pharmaceuticals LP $56,721.38 01/22/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, P.C.
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185541648
Principal investigator 1 ABBVIE INC. $6,750.00 01/20/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202440096
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,185.01 01/15/2025 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190304767
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,617.50 01/14/2025 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixeddose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma No dispute reported 06/30/2026 1235995495
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 01/08/2025 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910503
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $9,520.00 01/08/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS 986205 in Participants with Muscle-Invasive Bladder Cancer No dispute reported 06/30/2026 1235992229